Research location
Sanford
Florida, United States
Advertisement
Research activity in Sanford
Florida, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 26 trials and 26 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Sanford
26 linked trials · page 1 of 1Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)NCT05485961 · 2024-04-27 · 1 site observation
RECRUITING
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or OverweightNCT06588283 · 2024-09-30 · 1 site observation
COMPLETED
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With AlbuminuriaNCT06150924 · 2023-12-14 · 1 site observation
COMPLETED
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With HypertensionNCT05968430 · 2023-07-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney DiseaseNCT05099770 · 2022-01-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Quadripolar CRT-D On Currently Approved Lead SystemSNCT02232984 · 2014-10-01 · 1 site observation
COMPLETED
A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With MetforminNCT02205528 · 2014-08-18 · 1 site observation
COMPLETED
24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and HypertensionNCT02182830 · 2014-07-25 · 1 site observation
COMPLETED
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHFNCT01870778 · 2013-10-02 · 1 site observation
COMPLETED
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of SchizophreniaNCT01939548 · 2013-10-01 · 1 site observation
TERMINATED
Pediatric Open-Label Extension StudyNCT01914393 · 2013-09-30 · 1 site observation
COMPLETED
Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 DiabetesNCT01831765 · 2013-08-26 · 1 site observation
COMPLETED
Pediatric Schizophrenia Efficacy and Safety StudyNCT01911429 · 2013-08-01 · 1 site observation
COMPLETED
Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)NCT01854658 · 2013-07-01 · 1 site observation
COMPLETED
Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 DiabetesNCT01834274 · 2013-06-01 · 1 site observation
TERMINATED
A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin AloneNCT01555164 · 2012-06-01 · 1 site observation
COMPLETED
Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive DisorderNCT01564862 · 2012-04-01 · 1 site observation
COMPLETED
Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 DiabetesNCT01512979 · 2012-01-01 · 1 site observation
COMPLETED
A Long-Term Safety Study of Pomaglumetad Methionil in SchizophreniaNCT01487083 · 2011-12-01 · 1 site observation
TERMINATED
Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual DysfunctionNCT01364649 · 2011-06-01 · 1 site observation
COMPLETED
A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia PatientsNCT01328093 · 2011-04-01 · 1 site observation
TERMINATED
Immunosafety Study of Recombinant Human Insulins in Type 1 DiabeticsNCT01308437 · 2011-03-01 · 1 site observation
TERMINATED
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)NCT01318434 · 2011-02-01 · 1 site observation
COMPLETED
Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes MellitusNCT00789750 · 2009-04-01 · 1 site observation
COMPLETED
A Safety, Efficacy and Tolerability Study of SEP-225289NCT00584974 · 2007-12-01 · 1 site observation
COMPLETED
Iressa Expanded Access Program (EAP)NCT00034879 · 2000-08-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.